Patents by Inventor Stephen P. Goff

Stephen P. Goff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10562939
    Abstract: Increased viral particle maturation and production can be achieved in various methods for producing viral particles from viral proteins, in general, by inhibiting or preventing Heme Oxygenase 2 (HO-2) from binding to the group-specific antigen (Gag) of the viral proteins, thus allowing delivery of the viral proteins to plasma membranes where they can replicate and mature without interference from HO-2. The increase in viral particle maturation and production can also be achieved by minimizing or eliminating the presence of HO-2 to thus reduce or prevent binding of HO-2 to the group-specific antigen (Gag) of the viral proteins. The invention is particularly applicable to the production of lentiviruses from viral proteins wherein the Matrix domain (MA) of the Gag is myristoylated.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: February 18, 2020
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Stephen P. Goff, Yiping Zhu, Liang Tong, Shukun Luo
  • Publication number: 20190153038
    Abstract: Increased viral particle maturation and production can be achieved in various methods for producing viral particles from viral proteins, in general, by inhibiting or preventing Heme Oxygenase 2 (HO-2) from binding to the group-specific antigen (Gag) of the viral proteins, thus allowing delivery of the viral proteins to plasma membranes where they can replicate and mature without interference from HO-2. The increase in viral particle maturation and production can also be achieved by minimizing or eliminating the presence of HO-2 to thus reduce or prevent binding of HO-2 to the group-specific antigen (Gag) of the viral proteins. The invention is particularly applicable to the production of lentiviruses from viral proteins wherein the Matrix domain (MA) of the Gag is myristoylated.
    Type: Application
    Filed: May 31, 2017
    Publication date: May 23, 2019
    Inventors: Stephen P. GOFF, Yiping ZHU, Liang TONG, Shukun LUO
  • Publication number: 20140272974
    Abstract: This invention relates to a novel retroelement, named “Steamer”, found in mollusks, more specifically Mya arenaria, that is associated with haemic neoplasia in these organisms. Haemic neoplasia (HN) is a recognizable leukemic-like disease. The invention provides the retroelement protein, antibodies to the protein, nucleic acids encoding the protein, probes, primer, gene constructs comprising the nucleic acids, host cells comprising the nucleic acids, and methods of using.
    Type: Application
    Filed: March 17, 2014
    Publication date: September 18, 2014
    Applicant: The Trustees of Columbia University in the City of New York
    Inventors: Stephen P. Goff, W. Ian Lipkin, Gloria Arriagada, Carol Reinisch, James Sherry, Charles Walker
  • Patent number: 8443739
    Abstract: Through the addition of tertiary air and a reduction of secondary air, NOx emissions from a waste-to-energy (WTE) boiler may be reduced. The tertiary air is added to the WTE at a distance from the secondary air, in a boiler region of relatively lower temperatures. A secondary NOx reduction system, such as a selective non-catalytic reduction (SNCR) system using ammonia or urea, may also be added to the boiler with tertiary air to achieve desirable high levels of NOx reductions. The SNCR additives are introduced to the WTE boiler proximate to the tertiary air.
    Type: Grant
    Filed: January 26, 2011
    Date of Patent: May 21, 2013
    Assignee: Covanta Energy Corporation
    Inventors: Stephen P. Goff, Mark L. White, Stephen G. Deduck, John D. Clark, Christopher A. Bradley, Robert L. Barker, Zenon Semanyshyn
  • Publication number: 20110117505
    Abstract: Through the addition of tertiary air and a reduction of secondary air, NOx emissions from a waste-to-energy (WTE) boiler may be reduced. The tertiary air is added to the WTE at a distance from the secondary air, in a boiler region of relatively lower temperatures. A secondary NOx reduction system, such as a selective non-catalytic reduction (SNCR) system using ammonia or urea, may also be added to the boiler with tertiary air to achieve desirable high levels of NOx reductions. The SNCR additives are introduced to the WTE boiler proximate to the tertiary air.
    Type: Application
    Filed: January 26, 2011
    Publication date: May 19, 2011
    Applicant: Covanta Energy Corporation
    Inventors: Stephen P. Goff, Mark L. White, Stephen G. Deduck, John D. Clark, Christopher A. Bradley, Robert L. Barker, Zenon Semanyshyn
  • Publication number: 20080149010
    Abstract: Through the addition of tertiary air and a reduction of secondary air, NOx emissions from a waste-to-energy (WTE) boiler may be reduced. The tertiary air is added to the WTE at a distance from the secondary air, in a boiler region of relatively lower temperatures. A secondary NOx reduction system, such as a selective non-catalytic reduction (SNCR) system using ammonia or urea, may also be added to the boiler with tertiary air to achieve desirable high levels of NOx reductions. The SNCR additives are introduced to the WTE boiler proximate to the tertiary air.
    Type: Application
    Filed: October 4, 2007
    Publication date: June 26, 2008
    Inventors: Stephen P. Goff, Mark L. White, Stephen G. Deduck, John D. Clark, Christopher A. Bradley, Robert L. Barker, Zenon Semanyshyn
  • Patent number: 6812025
    Abstract: This invention provides methods of determining whether a compound inhibits HIV-1 reverse transcriptase. This invention provides methods of determining whether a compound inhibits formation of a complex between a p66 and p51 subunit polypeptides of HIV-1 reverse transcriptase. This invention provides a method of determining whether a compound enhances formation of a complex between a p66 and p51 subunit polypeptides of HIV-1 reverse transcriptase. This invention provides methods of determining whether a compound inhibits formation of a complex between two p66 subunit polypeptides of HIV-1 reverse transcriptase. This invention provides methods of determining whether a compound enhances formation of a complex between two p66 subunit polypeptides of HIV-1 reverse transcriptase.
    Type: Grant
    Filed: June 12, 2002
    Date of Patent: November 2, 2004
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Stephen P. Goff, Gilda Tachedjian
  • Publication number: 20030007983
    Abstract: This invention provides methods of determining whether a compound inhibits HIV-1 reverse transcriptase. This invention provides methods of determining whether a compound inhibits formation of a complex between a p66 and p51 subunit polypeptides of HIV-1 reverse transcriptase. This invention provides a method of determining whether a compound enhances formation of a complex between a p66 and p51 subunit polypeptides of HIV-1 reverse transcriptase. This invention provides methods of determining whether a compound inhibits formation of a complex between two p66 subunit polypeptides of HIV-1 reverse transcriptase. This invention provides methods of determining whether a compound enhances formation of a complex between two p66 subunit polypeptides of HIV-1 reverse transcriptase.
    Type: Application
    Filed: December 6, 2001
    Publication date: January 9, 2003
    Inventors: Stephen P. Goff, Gilda Tachedjian, Bryan Mark O'Hara
  • Publication number: 20020197598
    Abstract: This invention provides methods of determining whether a compound inhibits HIV-1 reverse transcriptase. This invention provides methods of determining whether a compound inhibits formation of a complex between a p66 and p51 subunit polypeptides of HIV-1 reverse transcriptase. This invention provides a method of determining whether a compound enhances formation of a complex between a p66 and p51 subunit polypeptides of HIV-1 reverse transcriptase. This invention provides methods of determining whether a compound inhibits formation of a complex between two p66 subunit polypeptides of HIV-1 reverse transcriptase. This invention provides methods of determining whether a compound enhances formation of a complex between two p66 subunit polypeptides of HIV-1 reverse transcriptase.
    Type: Application
    Filed: June 12, 2002
    Publication date: December 26, 2002
    Inventors: Stephen P. Goff, Gilda Tachedjian
  • Patent number: 6469153
    Abstract: This invention provides isolated nucleic acid molecules encoding envelope-interacting protein-1 and envelope-interacting protein-3. This invention provides fusion proteins comprising EIP-1, EIP-3, or fragments thereof and a second peptide. This invention provides vectors comprising the isolated nucleic acid molecule, encoding mammalian EIP-1 and EIP-3. This invention provides plasmid designated pCGN-EIP-l and pCGN-EIP-3. This invention provides purified mammalian EIP-1 and EIP-3 proteins. This invention provides monoclonal or polyclonal antibodies directed to epitopes of an EIP-1 or an EIP-3. This invention provides a method of increasing transduction efficieny of a retrovirus on target cells comprising: a) incubating an envelope-interacting protein with a retrovirus; and b) transducing the target cells with the retrovirus.
    Type: Grant
    Filed: May 20, 1998
    Date of Patent: October 22, 2002
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Stephen P. Goff, Xingqiang Li
  • Patent number: 6372502
    Abstract: This invention provides a mammalian cell useful for retroviral packaging comprising two plasmids, both of which comprise the 5′ long terminal repeat (LTR) sequence from a helper virus, neither of which comprise a functional &psgr; packaging sequence or a 3′ LTR from the helper virus, one of which comprises the env gene from the helper virus and the other of which comprises the gag and pol genes from the helper virus. This invention also provides a process for preparing a producer cell useful for transferring a foreign gene into a mammalian cell which comprises treating the above-described mammalian cell with a vector plasmid so as to insert the vector plasmid into the cell and thus create the producer cell, the vector plasmid comprising the foreign gene, a functional &psgr; packaging sequence from the helper virus, both the 5′ and 3′ LTRS from the helper virus, and a gene encoding a selectable or identifiable phenotypic trait, and recovering the producer cell so created.
    Type: Grant
    Filed: November 17, 1994
    Date of Patent: April 16, 2002
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Arthur Bank, Dina G. Markowitz, Stephen P. Goff
  • Patent number: 6222024
    Abstract: Upon entry into a host cell, retroviruses direct the reverse transcription of the viral RNA genome and the establishment of an integrated proviral DNA. The retroviral integrase protein (IN) is responsible for the insertion of the viral DNA into host chromosomal targets. The IN catalyzes two specific biochemical reactions: (i) cleavage of the 3′termini of the viral DNA to produce 3′-OH ends, and (ii) joining of the two newly generated 3′-termini to the 5′-phosphates on each strand of the target sequence in a concerted strand-transfer reaction. The yeast two-hybrid system was used to identify a novel human gene product, herein designated integrase interactor 1 or INI-1, that binds tightly to the human immunodeficiency virus type 1 (HIV-1) integrase in vitro.
    Type: Grant
    Filed: May 24, 1994
    Date of Patent: April 24, 2001
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Stephen P. Goff, Ganjam V. Kalpana
  • Patent number: 6136582
    Abstract: This invention provides a polypeptide capable of polymerizing i) deoxyribonucleotides; ii) ribonucleotides; or iii) one or more deoxyribonucleotides and one or more ribonucleotides. This invention further provides a purified Moloney murine leukemia virus reverse transcriptase, wherein an amino acid corresponding to position 155 of a wild type Moloney murine leukemia virus reverse transcriptase is a valine. This invention also provides a method of polymerizing a nucleic acid molecule comprising one or more deoxyribonucleotides and one or more ribonucleotides comprising: contacting a polypeptide capable of polymerizing i) deoxyribonucleotides; ii) ribonucleotides; or iii) one or more deoxyribonucleotides and one or more ribonucleotides with deoxyribonucleotides and ribonucleotides under conditions permitting incorporation of deoxyribonucleotides and ribonucleotides into a nucleic acid molecule.
    Type: Grant
    Filed: January 20, 1998
    Date of Patent: October 24, 2000
    Assignee: The Trustees of Columbia University in the City
    Inventors: Guangxia Gao, Stephen P. Goff
  • Patent number: 5872213
    Abstract: Upon entry into a host cell, retroviruses direct the reverse transcription of the viral RNA genome and the establishment of an integrated proviral DNA. The retroviral integrase protein (IN) is responsible for the insertion of the viral DNA into host chromosomal targets. The IN catalyzes two specific biochemical reactions: (i) cleavage of the 3'termini of the viral DNA to produce 3'-OH ends, and (ii) joining of the two newly generated 3'-termini to the 5'-phosphates on each strand of the target sequence in a concerted strand-transfer reaction. The yeast two-hybrid system was used to identify a novel human gene product, herein designated integrase interactor 1 or INI-1, that binds tightly to the human immunodeficiency virus type 1 (HIV-1) integrase in vitro. Approximately 10.sup.6 complementary DNAs (cDNAs) of the HL60 macrophage-monocytic cell line were expressed as GAL4AC (activation domain) fusions and tested for coactivation of a reporter gene together with a GAL4DB (DNA binding) IN fusion.
    Type: Grant
    Filed: August 18, 1995
    Date of Patent: February 16, 1999
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Stephen P. Goff, Ganjam V. Kalpana
  • Patent number: 5773225
    Abstract: The human immunodeficiency virus type 1 (HIV-1) gag gene product is capable of directing the assembly of virion particles independent of other viral elements. The Gag protein also plays an important role during the early stages of viral replication. Employing the yeast two-hybrid system, a cDNA expression library was screened and two host proteins identified. These proteins, designated cyclophilins A and B (CyPsA and B), interacted specifically with the HIV-1 Gag polyprotein Pr55.sup.gag. Glutathione S-transferase-CyP fusion proteins bind tightly to Pr55.sup.gag in vitro. Cyclosporin A (CsA) efficiently disrupts the Gag-CyPA binding interaction. The identification of novel compounds capable of abrogating this protein-protein interaction employing the disclosed screening assay will facilitate the development of HIV-1 antiviral agents.
    Type: Grant
    Filed: May 24, 1994
    Date of Patent: June 30, 1998
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Jeremy Luban, Stephen P. Goff
  • Patent number: 5405537
    Abstract: This invention relates to an improved process for the coincineration of municipal solid waste and municipal sewage sludge by dewatering the sludge, breaking it up into sufficiently small particles and employing oxygen enrichment of the combustion process. These small particles of sludge are introduced into the combustion zone above the grate in the combustion zone but at a distance above the grate no higher than that of the point of introduction of secondary air. This is accomplished without undesired excursions of flue gas flow rate and temperature.
    Type: Grant
    Filed: March 26, 1993
    Date of Patent: April 11, 1995
    Assignee: Air Products and Chemicals, Inc.
    Inventors: Stephen P. Goff, Diane M. DeVincentis, Shoou-I Wang, Donald P. Bucci, Frank J. Romano, Goutam H. Shahani, Matthew J. Foder
  • Patent number: 5347073
    Abstract: Fly ash generated from incineration of municipal solid waste (MSW) when placed in landfills can under mild acid conditions 1each lead and cadmium. A process for stabilizing lead in this fly ash is presented which involves calcining a mixture of the fly ash and certain calcium-containing compounds in the presence of an oxygen containing gas stream at a temperature greater than about 475.degree. C. and less than about 600.degree. C. for times from about 30 minutes up to about 5 hours. Such treated MSW fly ash will give leachates containing lead concentrations less than the EPA regulatory limit.
    Type: Grant
    Filed: April 28, 1993
    Date of Patent: September 13, 1994
    Assignee: Air Products and Chemicals, Inc.
    Inventors: Wolfgang A. Hochleitner, Stephen P. Goff
  • Patent number: 5347074
    Abstract: Fly ash generated from incineration of municipal solid waste (MSW) when placed in landfills can under mild acid conditions can leach lead and cadmium. A process for stabilizing heavy metals in this fly ash is presented which involves calcining the fly ash in the presence of an oxygen containing gas stream at a temperature greater than about 400.degree. C. and less than about 600.degree. C. for times from about 170 seconds up to about 5 hours fly ash which has been subjected to calcium scrubbing for acid gas removal. Such treated MSW fly ash will give leachates containing heavy metal concentrations less than the EPA regulatory limit.
    Type: Grant
    Filed: April 27, 1993
    Date of Patent: September 13, 1994
    Assignee: Air Products and Chemicals, Inc.
    Inventors: Wolfgang A. Hochleitner, Stephen P. Goff
  • Patent number: 5284636
    Abstract: A process for the stabilization of heavy metals in the ash produced by the combustion of a heavy metals containing fuel, such as municipal solid waste, by introducing into the combustion system a phosphorous oxide specie or elemental yellow phosphorus. The additive can be introduced at any point in the system upstream of the particulate removal device employed in the system. If elemental phosphorus is used, it must be introduced at a point in the system where it will be exposed to an elevated temperature and oxygen, so as to be converted to a phosphorus oxide specie. When elemental phosphorus is introduced into the system downstream of the combustion zone, it is also effective to reduce the NO content of the flue gas.
    Type: Grant
    Filed: March 25, 1992
    Date of Patent: February 8, 1994
    Assignee: Air Products and Chemicals, Inc.
    Inventors: Stephen P. Goff, John J. Lewnard, Shoou-I Wang
  • Patent number: 5278056
    Abstract: The invention relates to a mammalian cell line useful for retroviral packaging comprising two plasmids, the first such plasmid comprising in 5' to 3' order: a DNA sequence comprising a 5' long terminal repeat (LTR); a mutated .psi. packaging sequence; a DNA sequence comprising the encoding portion of the Moloney murine leukemia virus (MULV) env gene; and the second such plasmid comprising in 5' to 3' order: a DNA sequence comprising a 5' long terminal repeat (LTR); a mutated .psi. packaging sequence; a DNA sequence comprising the encoding portion of the Moloney murine leukemia virus (MULV) gag and pol genes; a selectable marker; and an origin of replication.The invention also relates to processes for preparing a producer cell line useful for transferring a gene of interest into recipient mammalian cells in vitro.
    Type: Grant
    Filed: April 29, 1992
    Date of Patent: January 11, 1994
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Arthur Bank, Dina G. Markowitz, Stephen P. Goff